Floatz logo

Daratumumab-Hyaluronidase

Renal Failure

Augusta UniversityEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Renal Failure cohort.

Asset / SponsorPhaseRating
NORMAL HUMAN SERUM ALBUMIN
Anna Cruceta
Phase 4BBB
DEXAMETHASONE
Augusta University
Phase 3BB
Midodrine
Anna Cruceta
Phase 4BB
TENOFOVIR DISOPROXIL FUMARATE
Thomas Benfield
Phase 4BB
Envarsus Product
University of Alberta
Phase 4BB

View all 50 →

Same molecule, other indications

Daratumumab-Hyaluronidase is also rated in:

plasma cell myelomaDormant
B
Indicative ·
62 / 100
View asset →
Non-small Cell Lung Cancer With STK11/LKB1 MutationDormant
B
Indicative ·
57 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →